Novartis AG Form 6-K Summary: Full Year 2004 Results
Business Context and Reporting Period
This Form 6-K, dated January 20, 2005, reports the fourth-quarter and full-year 2004 financial results for Novartis AG, a global leader in pharmaceuticals and consumer health headquartered in Basel, Switzerland. The reporting period covers the fiscal year ended December 31, 2004. The company operates primarily through two divisions: Pharmaceuticals and Consumer Health.
Key Financial Metrics
| Metric | Full Year 2004 (USD m) | Full Year 2003 (USD m) | % Change |
|---|---|---|---|
| Net Sales | 28,247 | 24,864 | 14% |
| Pharmaceuticals Net Sales | 18,497 | 16,020 | 15% |
| Consumer Health Net Sales | 9,750 | 8,844 | 10% |
| Operating Income | 6,539 | 5,889 | 11% |
| Operating Margin | 23.1% | 23.7% | -0.6 pp |
| Net Income | 5,767 | 5,016 | 15% |
| Basic EPS (USD) | 2.36 | 2.03 | 16% |
| Cash Flow from Operating Activities | 6,725 | 6,652 | 1% |
| Free Cash Flow | 3,359 | 3,628 | -7% |
| Net Liquidity | 7,738 | 7,289 | 6% |
| Debt/Equity Ratio | 0.20:1 | 0.20:1 | Stable |
Material Changes vs. Prior Period
- Revenue Growth: Group net sales increased 14% in USD (9% in local currencies). Growth was driven by volume (+8 percentage points) and favorable currency effects (+5 percentage points). Pharmaceuticals grew 15% and Consumer Health 10%.
- Profitability: Operating income rose 11% to $6.5 billion. While Pharmaceuticals operating income surged 19% with margin expansion to 28.4%, Consumer Health operating income declined 11% to $1.2 billion due to one-time charges.
- Product Performance: Key blockbusters Diovan ($3.1B sales), Gleevec/Glivec (+45%), and Femara (+70%) drove growth. Conversely, Sandoz (generics) sales grew only 5% due to competitive pricing pressures and a strong prior-year comparison.
- Acquisitions: Significant 2004 acquisitions included Sabex Holdings (generics) and the adult medical nutrition business of Mead Johnson, contributing to sales and goodwill.
Guidance, Outlook, and Risks
- 2005 Outlook: Management expects high single-digit net sales growth for the Group and Pharmaceuticals in local currencies. Operating and net income are projected to reach new record levels on a comparable basis.
- Accounting Changes: The company anticipates expensing share-based compensation in 2005, which will impact reported earnings.
- Risks and Contingencies:
- Legal: A $51 million provision was recorded in Medical Nutrition for a US Department of Justice investigation into the enteral pump market; negotiations for a settlement are ongoing.
- Regulatory: Forward-looking statements regarding new product approvals (e.g., Diovan for heart attack patients, Zelnorm in the EU) are subject to regulatory delays or rejections.
- Market: Pricing pressures in the generics sector (Sandoz) and competition in key therapeutic areas remain risks.
- Dividend: The Board proposed a dividend of CHF 1.05 per share for 2004, an increase from CHF 1.00 in 2003.
Investor Verification Checklist
- Verify the impact of the proposed share-based compensation expense on 2005 earnings guidance.
- Monitor the status of the US Department of Justice investigation regarding Novartis Nutrition Corporation and potential settlement costs.
- Assess the sustainability of double-digit growth in the Oncology franchise (Gleevec, Femara, Zometa) amidst potential patent expirations or competition.
- Review the performance of the Sandoz generics division given the noted competitive pricing pressures in the US and Germany.
- Confirm the regulatory approval timeline for Zelnorm in the European Union and Diovan for high-risk heart attack patients in the US.